



ASX/ Media release

12 November 2004

Pharmaxis Establishes Level One American Depositary Receipt (ADR) Program

Pharmaxis (ASX:PXS) is pleased to announce that the establishment of its Level One ADR Program has been declared effective by the US Securities and Exchange Commission (SEC) as from 12 November 2004. The Bank of New York was appointed as the depositary bank for the ADR program.

A Level One ADR Program facilitates the purchase of Pharmaxis shares by US investors. Under the program, one ADR is equivalent to 15 ordinary shares of Pharmaxis. The ADR's trade in the US over-the-counter (OTC) market under the symbol PHMXY (CUSIP number 71715J105).

Dr Alan Robertson, Chief Executive Officer of Pharmaxis said: "We are building an international pharmaceutical business. Establishing a Level One ADR Program is part of a broader initiative enabling international investment in the company, particularly by the important US capital markets."

About ADRs

ADR's are commonly used to facilitate the holding and trading of foreign securities by US residents which would otherwise be prohibited by US securities laws.

Level One Depositary Receipts are freely tradeable, just like any other security, in the US over-the-counter (OTC) market. Trading activity is available on the Bloomberg website: www.bloomberg.com

Level One ADR's do not necessitate compliance with US Generally Accepted Accounting Principles (US GAAP) or SEC disclosure other than that provided to a company's home stock exchange.

A Level Two ADR program is required for a company seeking to list on the NASDAQ or NYSE, and a Level Three program is required for a US public offering.

To find more detail about ADR's and the Bank of New York, go to <http://www.adrbny.com>.

To find out more about Pharmaxis, go to <http://www.pharmaxis.com.au>

ends#

For further information, please contact:

David McGarvey - Pharmaxis Chief Financial Officer

Ph: (02) 9454 7203 or david.mcgarvey@pharmaxis.com.au

Released through: - Ashley Rambukwella – Financial & Corporate Relations

Ph: (02) 8264 1004 / m. 0407 231 282 or a.rambukwella@fcr.com.au

About Pharmaxis (ACN 082 811 630)

Pharmaxis develops innovative pharmaceutical products to treat human respiratory and autoimmune diseases. Its pipeline of products include Aridol™ for the management of asthma, Bronchitol™ for cystic fibrosis and chronic obstructive pulmonary disease (COPD) and PXS25 for the treatment of multiple sclerosis.

Founded in 1998, Pharmaxis was listed on the Australian Stock Exchange in November 2003 and is traded under the symbol PXS. The company is headquartered in Sydney at its TGA-approved manufacturing facilities.

For more information about Pharmaxis, go to www.pharmaxis.com.au or call +61 2 9451 5961.
